Highlights Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:03 15/05/2026 BST			5-day change	1st Jan Change
169.12 ^USD	-0.91%		-5.37%	-24.97%

05-13	IQVIA And Kexing Biopharm Expand Strategic Collaboration To Accelerate Global Biosimilar Development Using AI-Enabled Capabilities	CI
05-13	IQVIA Holdings Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10:40 AM

Highlights

05-06	IQVIA Holdings Inc. announces an Increase in Equity Buyback.	CI
05-05	Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	CI
05-05	IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	IQVIA lifts annual profit forecast as pharma spending improves	RE
05-05	IQVIA Q1 Adjusted Earnings, Revenue Rise; Raises 2026 Adjusted Earnings Guidance	MT
05-05	(IQV) IQVIA Holdings Expects 2026 Revenue Range $17.15B - $17.35B, vs. FactSet Est of $17.24B	MT
05-05	(IQV) IQVIA Expects 2026 Adjusted EPS Range $12.65 to $12.95, vs. FactSet Est of $12.71	MT
05-05	Earnings Flash (IQV) IQVIA Holdings Inc. Reports Q1 Revenue $4.15B, vs. FactSet Est of $4.10B	MT
05-05	Earnings Flash (IQV) IQVIA Holdings Inc. Posts Q1 Adjusted EPS $2.90 per Share, vs. FactSet Est of $2.82	MT
05-05	IQVIA Holdings Inc. Reaffirms Earnings Guidance for the Full-Year 2026	CI
02-25	IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million.	CI
02-25	Charles River raises annual profit view as it sells underperforming assets	RE
02-25	Iqvia signs agreement to acquire drug discovery assets from Charles River Laboratories, expanding end-to-end drug discovery capabilities	RE
02-10	IQVIA, Duke Clinical Research Institute to Collaborate on Obesity Research	MT
02-10	IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions	CI
02-05	IQVIA backs AI strategy as analysts question impact on business	RE
02-05	IQVIA Shares Fall After 2026 EPS Guidance Miss Expectations	MT
02-05	IQVIA forecasts weak annual profit on higher interest expenses	RE
02-05	IQVIA Holdings Inc. Provides Earnings Guidance for Full Year 2026	CI
02-05	Iqvia shares down 6.48% after co forecasts 2026 profit below estimates	RE
02-05	IQVIA Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-05	IQVIA Q4 Adjusted Earnings, Revenue Rise; Issues 2026 Guidance	MT
02-05	(IQV) IQVIA Expects 2026 Revenue Range $17.15B - $17.35B, vs. FactSet Est of $17.07B	MT
02-05	(IQV) IQVIA Expects 2026 Adjusted EPS Range $12.55 to $12.85, vs. FactSet Est of $12.93	MT
02-05	Earnings Flash (IQV) IQVIA Holdings Inc. Posts Q4 Adjusted EPS $3.42 per Share, vs. FactSet Est of $3.40	MT